Teva Pharmaceutical Industries (TEVA) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

ProductDistribution ServiceProduct and Service, OtherLicense
0750M2B2B3B4B4B5B6BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue by Geography

North America SegmentEurope SegmentUnited States Segment
0875M2B3B4B4B5B6B7BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
01B2B3B4B6B7B8B9BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
01020304050607080Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Operating Expenses

Research And Development ExpensesSelling And Marketing ExpensesGeneral And Administrative ExpensesOther Expenses
0250M500M750M1B1B2B2B2BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
0112M225M338M450M562M675M788M900MQ1 2025Q2 2025

EPS

EPSEPS Diluted
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue Variation (%)

Revenue Variation
-10-8-5-3-02479Q1 2025Q2 2025

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
0815223038455260Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Revenue YoY Variation
000111222Q1 2025Q2 2025

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
012234456Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
048111519222630Q1 2025Q2 2025

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
048111519222630Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Per Share Metrics

Operating IncomeTotal Other Income Expenses NetNet Income
0112M225M338M450M562M675M788M900MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
011223445Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
💰 Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Free Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
075M150M225M300M375M450M525M600MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash Flow to Debt Ratio

Cash At End Of Period
0375M750M1B2B2B2B3B3BQ1 2025Q2 2025
🏦 Balance Sheet
📈 Key Metrics